XML 66 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Business Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenue from research and development collaborations $ 27,110 $ 10,030
Segment expenses:    
Total operating expenses 52,723 47,832
Segment loss (25,613) (37,802)
Reconciling items:    
Change in contingent consideration 0 700
Interest income 3,424 5,920
Other income, net 49 304
Income tax expense (496) (75)
Net loss (22,636) (31,653)
Reportable Segment    
Segment Reporting Information [Line Items]    
Revenue from research and development collaborations 27,110 10,030
Segment expenses:    
Salaries and benefits 13,840 13,348
Other research and development expense 4,848 3,741
Other general and administrative expense 7,475 8,283
Total operating expenses 43,723 43,217
Segment loss (16,613) (33,187)
Reconciling items:    
Depreciation and amortization (2,598) (1,763)
Stock-based compensation expense (6,402) (3,552)
Change in contingent consideration 0 700
Interest income 3,424 5,920
Other income, net 49 304
Income tax expense (496) (75)
Net loss (22,636) (31,653)
Reportable Segment | Zanidatamab    
Segment expenses:    
Research and development expense 1,403 3,388
Reportable Segment | ZW171    
Segment expenses:    
Research and development expense 2,226 2,298
Reportable Segment | ZW191    
Segment expenses:    
Research and development expense 1,706 2,726
Reportable Segment | ZW220    
Segment expenses:    
Research and development expense 2,199 3,367
Reportable Segment | ZW251    
Segment expenses:    
Research and development expense 3,951 607
Reportable Segment | Zanidatamab zovodotin    
Segment expenses:    
Research and development expense 349 2,649
Reportable Segment | Expense for other preclinical and research programs    
Segment expenses:    
Research and development expense $ 5,726 $ 2,810